SS Innovations Q2 revenue up 39% to $13.9M; net loss widens to $2.7M

SS Innovations International, Inc.

2026-Q2 EPS reported -$0.03 revenue$25,041,075

Revenue $13.9M, +39.4% YoY; gross margin 50.9% vs 59.1% prior year.
Net loss $2.7M ($0.01/share) vs $0.3M loss in Q2 2025.
SSi Mantra installations 30 in Q2 (+30.4%); cumulative base 224 systems, 12,272 surgeries.
H1 revenue $25.0M (+65.6%); net loss $6.2M vs $5.9M.
FDA 510(k) decision expected by end Q1 2027; EU CE mark targeted by end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.